Company Overview
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris has the ambition to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy to prevent and treat angioedema attacks.
Deucrictibant is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Pharvaris is developing two distinct formulations of deucrictibant to address unmet needs in both the on-demand (via immediate-release capsule) and prophylactic (via extended-release tablet) hereditary angioedema (HAE) treatment paradigms.
With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further clinical development of deucrictibant. Pharvaris is currently evaluating the efficacy and tolerability of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3).
